Dresner Foundation Names Mikkael Aaron Sekeres, MD, MS, as Chair, Myelodysplastic Syndromes Research Fund

The Dresner Foundation Board of Directors announced the appointment of Mikkael Aaron Sekeres, MD, MS, as the Chair of the Foundation’s Myelodysplastic Syndromes (MDS) Research Fund. This national initiative will provide grant support for innovative MDS basic science, clinical and translational research.

“Dr. Sekeres’ energy, experience and passion for this field of work immediately captured the attention of the Directors, who unanimously selected him as the inaugural Chair,” said Lori Dresner, Board President. “Dr. Sekeres aligned with our goal of engaging a national thought leader with demonstrated scientific credibility to advance the understanding and treatment of MDS and related blood disorders and its cure.”

Dr. Sekeres is a Professor of Medicine at Cleveland Clinic in the Department of Hematology and Medical Oncology, Director of the Leukemia Program and Vice-Chair for Clinical Research at the Cleveland Clinic – Taussig Cancer Center. He holds a B.A. in Biology, Master’s of Science in Clinical Epidemiology, and M.D. from the University of Pennsylvania. He completed his Internal Medicine Residency at Massachusetts General Hospital and Hematology-Oncology Fellowship at Dana-Farber Cancer Institute, both Harvard University affiliated institutions.

“I am honored and humbled to have been selected to help translate Joseph Dresner’s vision for research in MDS into the next generation of exciting therapies and potential cures.”

Dr. Sekeres formally assumed this role January 1, 2017.

For more information, please contact Virginia Romano, Dresner Foundation, 248-785-0299.